Torrent Pharmaceuticals : Strengthening Healthcare Access Worldwide

Introduction to Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd., the flagship company of the Torrent Group, is a leading Indian multinational pharmaceutical organization with a strong presence in over 50 countries. The Company was a pioneer in initiating the concept of niche marketing in India and today is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments.The company operates in 50+ countries with subsidiaries in key markets like the U.S., Germany, Brazil, and the UK. It has over 2,000 product registrations globally and 101 ANDA approvals in the U.S., with 34 more in the pipeline.Torrent operates eight world-class manufacturing plants and a state-of-the-art R&D center. Its facilities are certified by global regulatory bodies such as USFDA, MHRA (UK), and TGA (Australia).Torrent is headquartered in Ahmedabad, Gujarat, India.

Incorporation – Torrent Pharmaceuticals was established in 1959 by U. N. Mehta as Trinity Laboratories. It was renamed as Torrent Pharmaceuticals in 1971.

Mission and Vision 

Mission:  To become the Most Respected Pharma Company.

Vision: They commit themselves to total customer care by delivering world-class products and services.

Founder Details

Mr. Uttambhai Nathalal Mehta the Founder- Chairman of the Torrent Group, who was a great businessman, a philanthropist. Mr. U. N. Mehta was one of those rare corporate leaders in Gujarat, who also understood the importance of having a good interface between business and community service. Perhaps that explains Mr. Mehta’s endeavours to establish and maintain robust relationship with the society.

U.N Mehta was born in Mehmadpur, Palanpur district in 1924. While living at the Mahavir Jain Vidyalay hostel, he earned his B.Sc. from Wilson College. He began his career as a government servant. From 1945 through 1958, he worked as a medical representative for the pharmaceutical corporation Sandoz.t was in 1959, that U.N Mehta made the ground-breaking decision to establish his own company, Trinity Laboratories, with a starting capital of only Rs 25,000. This organization began producing specialized medications.He received various honors, including the Government of India’s ‘Business Man of the Year’ award in 1996-97.

Products of Torrent Pharmaceuticals

Torrent Pharmaceuticals Ltd. offers a diverse range of products across various therapeutic areas, catering to both branded and generic markets.

Torrent Pharma specializes in several therapeutic segments, including:Cardiovascular (CV), Central Nervous System (CNS), Gastrointestinal (GI), Diabetology, Pain Management, Anti-Infectives, Vitamins, Minerals, and Nutritionals (VMN), Nephrology, Oncology, Gynecology, Pediatrics, Pulmonology.

Funding Details of Torrent Pharmaceuticals

Torrent Pharmaceuticals has received $40 million in investment in one round. On April 3, 2014, a Post-IPO Equity round was raised. Chrys Capital, an investment firm focused in India, is the company, which has invested in Torrent Pharmaceuticals.

IPO Details of Torrent Pharmaceuticals

BONUS

DIVIDEND for 2020-2024

Acquisition of Torrent Pharmaceuticals

Torrent Pharmaceuticals has been actively pursuing acquisitions to strengthen its portfolio and market presence across various therapeutic segments. In September 2022, Torrent Pharmaceuticals announced the acquisition of 100% of Curatio Healthcare for ₹2,000 crore (approximately $245.16 million). This acquisition included ₹115 crore in cash and cash equivalents, valuing the enterprise at ₹1,885 crore. Curatio specializes in cosmetic dermatology with a portfolio of over 50 brands, including popular products like Tedibar, Atogla, Spoo, B4 Nappi, and Permite. In December 2024, Torrent entered into an agreement to acquire three anti-diabetes brands—Cospiaq, Cospiaq Met, and Xilingio—from Boehringer Ingelheim. Torrent had been marketing these brands since 2022 under a co-marketing agreement. This acquisition is expected to be completed by March 2025 and is part of Torrent’s strategy to strengthen its presence in the diabetes care market,

Revenue and Growth of Torrent Pharmaceuticals

As of 30-Sep-2024, Torrent Pharmaceuticals has a trailing 12-month revenue of $1.32B.

Awards and Recognitions of Torrent Pharmaceuticals

Torrent Pharma has won many awards such as:

• It was listed amongst the top five ‘Fastest Growing Companies (Middleweights Category)’ by Business World Magazine – in 2017
• Torrent Pharma’s manufacturing plant in Dahej, received USFDA approval – in 2016
• Torrent Pharma was recognized as the Most Promising Company of the Year at the 10th CNBC TV18 India Business Leader Awards 2014

Competitors of Torrent Pharmaceuticals

• • Sun Pharmaceuticals
  • Cipla Ltd.
  • Reddy’s Laboratories Ltd.
  • Ajanta Pharma
  • Instas Pharmaceuticals
  • Lupin Ltd.

Conclusion

Torrent Pharmaceuticals has emerged as a global leader by leveraging its innovative capabilities, strategic acquisitions, robust manufacturing infrastructure, and strong therapeutic focus. Its commitment to quality, research-driven growth, and customer-centric approach has positioned it as a trusted name in healthcare worldwide. With continued investments in R&D and expansion into new markets, Torrent Pharma is poised for sustained growth while contributing meaningfully to global healthcare solutions.

GetMyIndia.com  RaysVeda.com  GetMyStartup.com  LawCanal.com  ABHAYRAY.COM  ZinCob.com